Cargando…

PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells

Over expression of various immunogenic melanoma associated antigens (MAAs) has been exploited in the development of immunotherapeutic melanoma vaccines. Expression of MAAs such as MART-1 and gp100 is modulated by the MAPK signaling pathway, which is often deregulated in melanoma. The protein BRAF, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	George, Andrea L., Suriano, Robert, Rajoria, Shilpi, Osso, Maria C., Tuli, Neha, Hanly, Elyse, Geliebter, Jan, Arnold, Angelo N., Wallack, Marc, Tiwari, Raj K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643088/ https://www.ncbi.nlm.nih.gov/pubmed/26640592 http://dx.doi.org/10.7150/jca.11126

Ejemplares similares

Ex Vivo Derived Primary Melanoma Cells: Implications for Immunotherapeutic Vaccines
por: Suriano, Robert, et al.
Publicado: (2013)

PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism
por: Garbarino, Ombretta, et al.
Publicado: (2023)

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype
por: Hanly, Elyse K, et al.
Publicado: (2014)

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
por: Niehr, Franziska, et al.
Publicado: (2011)

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
por: Jenkins, Molly H., et al.
Publicado: (2015)

Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
por: Su, Xi, et al.
Publicado: (2021)

Differential sensitivity of melanoma cell lines with BRAF(V600E )mutation to the specific Raf inhibitor PLX4032
por: Søndergaard, Jonas N, et al.
Publicado: (2010)

Galectin-3 sensitized melanoma cell lines to vemurafenib (PLX4032) induced cell death through prevention of autophagy
por: Bustos, Silvina Odete, et al.
Publicado: (2018)

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors
por: Choi, Jaehyuk, et al.
Publicado: (2014)

Adaptive up-regulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
por: Basile, Kevin J., et al.
Publicado: (2011)

Induced cross-resistance of BRAF(V600E) melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment
por: Erdmann, Sarah, et al.
Publicado: (2019)

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
por: Rubinstein, Jill C, et al.
Publicado: (2010)

HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF(V600E) Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia
por: Furfaro, Anna Lisa, et al.
Publicado: (2022)

Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells
por: Li, Yanling, et al.
Publicado: (2015)

Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression
por: Michaelis, Martin, et al.
Publicado: (2014)

Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells
por: Hanly, Elyse K., et al.
Publicado: (2015)

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells
por: Halaban, Ruth, et al.
Publicado: (2010)

Estrogen Induced Metastatic Modulators MMP-2 and MMP-9 Are Targets of 3,3′-Diindolylmethane in Thyroid Cancer
por: Rajoria, Shilpi, et al.
Publicado: (2011)

Molecular target based combinational therapeutic approaches in thyroid cancer
por: Rajoria, Shilpi, et al.
Publicado: (2012)

Macrophage inflammatory factors promote epithelial-mesenchymal transition in breast cancer
por: Bednarczyk, Robert B., et al.
Publicado: (2018)

Hypoxia and estrogen are functionally equivalent in breast cancer-endothelial cell interdependence
por: George, Andrea L, et al.
Publicado: (2012)

Berberine Inhibits Human Melanoma A375.S2 Cell Migration and Invasion via Affecting the FAK, uPA, and NF-κB Signaling Pathways and Inhibits PLX4032 Resistant A375.S2 Cell Migration In Vitro
por: Liu, Jia-Fang, et al.
Publicado: (2018)

mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
por: Hanly, Elyse K., et al.
Publicado: (2015)

Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants
por: Shanmugam, Arulkumaran, et al.
Publicado: (2012)

Endothelial progenitor cell biology in disease and tissue regeneration
por: George, Andrea L, et al.
Publicado: (2011)

Antiproliferative Imidazo-Pyrazole-Based Hydrogel: A Promising Approach for the Development of New Treatments for PLX-Resistant Melanoma
por: Alfei, Silvana, et al.
Publicado: (2023)

Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
por: Zhang, Honglai, et al.
Publicado: (2018)

Gene master regulators of papillary and anaplastic thyroid cancers
por: Iacobas, Dumitru A., et al.
Publicado: (2017)

Biguanides and targeted anti-cancer treatments
por: Hanly, Elyse K., et al.
Publicado: (2015)

Melanoma antigens and antibodies
por: Embleton, M.J.
Publicado: (1983)

Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets
Publicado: (1982)

AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma
por: Conteduca, Giuseppina, et al.
Publicado: (2016)

Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma
por: Hanly, Ailish, et al.
Publicado: (2021)

Plx1 is required for chromosomal DNA replication under stressful conditions
por: Trenz, Kristina, et al.
Publicado: (2008)

Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study
por: Cazzato, Gerardo, et al.
Publicado: (2022)

Putting PLX5622 into perspective: microglia in central nervous system viral infection
por: Spiteri, Alanna G., et al.
Publicado: (2022)

Tumor-associated antigens in human malignant melanoma.
por: Lewis, M. G., et al.
Publicado: (1973)

Melanoma and Human Leukocyte Antigen (HLA): Immunogenicity of 69 HLA Class I Alleles With 11 Antigens Expressed in Melanoma Tumors
por: Georgopoulos, Apostolos P, et al.
Publicado: (2023)

B-lymphocytes from melanoma patients and normal individuals react with melanoma cells but also with irrelevant antigens.
por: Damato, B. E., et al.
Publicado: (1988)

ZAK Inhibitor PLX4720 Promotes Extrusion of Transformed Cells via Cell Competition
por: Maruyama, Takeshi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2q1vaa4jvnd53u1o6qn0nqdvu8